Perelman School of Medicine

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Previous studie

When skin cells responsible for pigmentation are exposed to estrogen or progesterone, the cells respond by adjusting their melanin production, resulting in either skin darkening or lightening. Although pregnant women often experience alterations in skin pigmentation, the reason for the changes has long puzzled physicians.

Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in&

Two Penn Medicine physicians – Ebbing Lautenbach, MD, MPH, MSCE, chief of the division of Infectious Diseases and the Robert Austrian Professor in the department of Medicine, and Ben Z.

Fragile X syndrome (FXS) is the most common genetically inherited cause of intellectual disability in humans.

Josep Dalmau, MD, PhD, an adjunct professor of neurology and founder and director of the Penn Center of Autoimmune Neurology in the Perelman School of Medicine at the University of Pennsylvania, was honored as a recipient of the American Academy of Neurology’s 2016 Cotzias Lecture and Award, at the organization’s 68th annual meeting that took place April 15-21 in Vancouver.

On top of the meaning and mystery that humans heap on the heart, it is first and foremost, a muscle. And one that beats about once a second for a person’s entire life, with no rest. Given its vital importance, it’s ironic researchers have only recently made direct observations of its subcellular parts in motion.

Beatrice H.

Asthma is an enormous public health problem that continues to grow larger, in part because scientists don’t fully understand how it is caused. Existing therapies don’t cure the disease and often don’t even significantly alleviate the symptoms.

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the